aflibercept in a sentence

• Regeneron commenced clinical testing of aflibercept in cancer in 2001.
• Aflibercept binds to circulating VEGFs and acts like a " VEGF trap ".
• Other approved antiangiogenic drugs for the treatment of neo-vascular AMD include pegaptanib and aflibercept.
• ZALTRAP ( aflibercept injection ) for metastatic colorectal cancer : Approved by the FDA in August 2012.
• Drugs such as aflibercept, bevacizumab, and ranibizumab can inhibit VEGF and control or slow those diseases.
• In 2003, Regeneon signed a major deal with Aventis to develop aflibercept in the field of cancer.
• In November 2012 the European Medicines Agency ( EMA ) approved aflibercept for the treatment of wet macular degeneration.
• As the active ingredient of Zaltrap, the substance is called "'ziv-aflibercept "'in the US.
• A 2016 Cochrane Review examined outcomes comparing aflibercept versus ranibizumab injections in over 2400 patients with neovascular AMD, from two randomized controlled trials.
• To avoid confusion with Eylea, the FDA assigned a new name, " ziv "-aflibercept, to the active ingredient.
• It's difficult to see aflibercept in a sentence .
• On July 29, 2014, Eylea ( aflibercept ), an intravitreal injection produced by Regeneron Pharmaceuticals Inc ., was approved to treat DME in the United States.
• In April 2011 Regeneron reported that aflibercept improved its primary endpoint of overall survival in the Velour phase III clinical trial for second-line treatment for metastatic colorectal cancer ( mCRC ).
• Both treatment options yielded similar improvements in visual acuity and morphological outcomes in patients, though the authors note that the aflibercept treatment regimen has the potential to reduce treatment burden other risks from injections.
• Aflibercept is being co-developed for cancer treatment by Sanofi and Regeneron under a deal signed in 2003, and is being co-developed for eye diseases by Bayer HealthCare and Regeneron under a deal signed in 2006.
• In 2003 Aventis entered into a collaboration with Regeneron, a New York biotechnology company, to develop Regeneron's VEGF-inhibiting drug, aflibercept, in the field of cancer, which was then in Phase I clinical trials.
• Lucentis has a similar but smaller molecular structure to Avastin, and is FDA-approved ( 2006 ) for treating MacD, yet remains more costly, as is the more recent ( approved in 2011 ) EYLEA ( aflibercept ).
• On August 3, 2012 the FDA approved aflibercept ( Zaltrap ) for use in combination with 5-fluorouracil, folinic acid and irinotecan to treat adults with metastatic colorectal cancer that is resistant to or has progressed following an oxaliplatin containing regimen.
• "' Aflibercept "'( Regeneron Pharmaceuticals, approved in the United States and Europe for the treatment of wet macular degeneration under the trade name "'Eylea "', and for metastatic colorectal cancer as "'Zaltrap " '.